Table 1.
Comparison of features of the currently available CGM systems.
| Dexcom G6 | FreeStyle Libre 2 | Eversense | Medtronic Guardian 3 | |
|---|---|---|---|---|
| Non-adjunctive Dosing | Approved | Approved | Approved | Not approved |
| Calibration | Not Required, Can perform | Not required, Cannot Perform | Every 12 hours | Every 12 hours |
| Sensor Warm-Up | 2 hours | 1 hour | ∼ 26 hours | Up to 2 hours |
| Sensor Wear Time | 10 days | 14 days (sensor/transmitter in one device) | 90 days | 7 days |
| Transmitter Wear Time | 90 days | 1 year | 1 year | |
| MARD | 9.0% a | 9.2% b | 8.5% c | 8.7%/ 9.1% d |
| Customizable Alarms for Hypo- / Hyperglycemia | Yes | Yes | Yes | Yes |
| Data Display | Dexcom Receiver or Smart Devices | FreeStyle Libre or Smart Devices | Dexcom Receiver or Smart Devices | 770G or Smart Device (Guardian Connect or MiniMed Mobile) |
| Follow App | Dexcom Share | LibreLinkUp | Eversense NOW | Carelink Connect |
| Interfering Substances- False Highs | Acetaminophen (>1 gram every 6 hrs) Hydroxyurea | Vitamin C | Mannitol (IV, local irrigation, peritoneal dialysis) | Acetaminophen (any dose) |
| Interfering Substances- False Lows | — | Aspirin | Tetracycline | — |
| AID Integration | Tandem Control IQ | No | No | Medtronic 770G |
*MARD, Mean Absolute Relative Difference; AID, Automated insulin delivery.
aShah VN, et al. Diabetes Technol Ther. 2018;20(6):428–433.
bFreeStyle Libre 2 User Manual.
cChristiansen MP, et al. Diabetes Technol Ther. 2019;21(5):231–237.
dChristiansen MP, et al. Diabetes Technol Ther. 2017;19(8):446–456.